Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Inebilizumab-cdon (Uplizna) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It has shown significant efficacy in reducing the risk of relapse, improving annualized relapse rates, and impacting disability progression.
• Four studies were reviewed, focusing on therapeutic options for NMOSD with particular emphasis on monoclonal antibodies, including Uplizna compared to other treatments.
• The safety analysis favored monoclonal antibodies like Uplizna, indicating a lower risk of serious adverse events compared to other treatments. A superior safety profile was observed with these new treatments, highlighting overall tolerability.
• Subgroup considerations suggest that eculizumab might offer an advantage in decreasing on-trial relapse risk among AQP4 positive patients, suggesting a potential preference within this subset of NMOSD patients.
• Accessibility and cost-related concerns associated with FDA-approved monoclonal antibodies such as Uplizna have been raised, suggesting off-label alternatives may serve as viable first-line options in resource-limited settings.
• While direct comparisons between Uplizna and other monoclonals like eculizumab or rituximab are scarce within the studies, grouped analysis favors the use of FDA-approved drugs, including Uplizna, due to their superior efficacy and safety despite higher costs.